Treatment May Protect Against Diet-Related ObesityLast Updated: June 22, 2009. Angiotensin-converting enzyme inhibition led to less gain of body weight and fat mass, as well as improved glucose tolerance in rats, according to research published online June 4 in Endocrinology.
MONDAY, June 22 (HealthDay News) -- Angiotensin-converting enzyme (ACE) inhibition led to less gain of body weight and fat mass, as well as improved glucose tolerance in rats, according to research published online June 4 in Endocrinology.
Annette D. de Kloet, of the University of Cincinnati, and colleagues discuss their experiments in which rats were given the ACE inhibitor, captopril, which doesn't effectively cross the blood-brain barrier.
The researchers found that rats eating a high-fat or a low-fat diet and receiving captopril weighed less than controls. The difference was due to less fat mass gained on either diet. The authors further note that rats treated with captopril ate significantly less -- despite heightened expression of neuropeptide-Y in the hypothalamic arcuate nucleus -- and had better glucose tolerance compared to controls.
"There are a number of reports of body weight and composition alterations in hypertensive patients during ACE inhibition; however, the mechanism(s) for these changes have not been unequivocally discerned, nor are these results constant among clinical reports and the different pharmacological agents used. Nevertheless, consistent with several recent reports, the present data provide additional support for a role for the renin-angiotensin-system in the control of energy balance and the potential for beneficial effects of captopril as a therapeutic strategy for patients with obesity and concomitant hypertension," the authors conclude.
A co-author reported financial associations with Zafgen, Ethicon Endo-Surgery, and Eli Lilly.
|Previous: Platelet Glue May Not Improve Spinal Fusion Rates||Next: Schizophrenia Linked to Increased Cancer Mortality|
Reader comments on this article are listed below. Review our comments policy.